G. Lavender Hackman

Ms. G. Lavender Hackman

University of Texas at Austin
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
CDCourtney Dinardo
Courtney Dinardo
DVDivij Verma
Divij Verma
Natalia BaranNatalia Baran
Natalia Baran
TBTushar D. Bhagat
Tushar D. Bhagat
ASAnna Skwarska
Anna Skwarska
MKMarina Konopleva
Marina Konopleva

10 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
G. Lavender HackmanG. Lavender Hackman
G. Lavender Hackman
Meghan CollinsMeghan Collins
Meghan Collins
XLXiyuan Lu
Xiyuan Lu
ALAlessia Lodi
Alessia Lodi
JDJohn Digiovanni
John Digiovanni
STStefano Tiziani
Stefano Tiziani
Natural products have been used for centuries to treat various human ailments. In recent decades, multi-drug combinations that utilize natural products to synergistically enhance the therapeutic effects of cancer drugs have been identified and have shown success in improving treatment outcomes. While drug synergy research is a burgeoning field, there are disagreements on the definitions and mathematical parameters that prevent the standardization and proper usage of the terms synergy, antagonism, and additivity. This contributes to the relatively small amount of data on the antagonistic effects of natural products on cancer drugs that can diminish their therapeutic efficacy and prevent cancer regression. The ability of natural products to potentially degrade or reverse the molecular activity of cancer therapeutics represents an important but highly under-emphasized area of research that is often overlooked in both pre-clinical and clinical studies. This review aims to evaluate the body of work surrounding the antagonistic interactions between natural products and cancer therapeutics and highlight applications for high-throughput screening (HTS) and deep learning techniques for the identification of natural products that antagonize cancer drug efficacy.

7 March 2024 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
MLMichael A. Liss
Michael A. Liss
FDFurkan Dursun
Furkan Dursun
G. Lavender HackmanG. Lavender Hackman
G. Lavender Hackman
MGMohamed I. Gadallah
Mohamed I. Gadallah
ASAchinto Saha
Achinto Saha
JDJohn Digiovanni
John Digiovanni
As screening strategies employ better biomarkers and genetics to identify individuals at an increased risk of prostate cancer, there are currently no chemotherapeutic prevention strategies. With any chemoprevention strategy, the population will be younger and healthier; therefore, they will be less tolerant of side effects. This study translated findings from screening a natural product library and pre-clinical evaluation of curcumin (CURC) in combination with ursolic acid (UA) in prostate cancer models. After manufacturing capsules for each compound, 18 subjects were enrolled. The study used a 3 × 3 phase 1 clinical trial to evaluate CURC (1200 mg/day) and UA (300 mg/day) alone and in combination over a 2-week period with endpoints of safety, bioavailability, and microbiome alterations. After enrolling six subjects in each arm, we found no grade 3 or 4 events and only minor changes in the safety laboratory values. In the pooled analysis of groups, we noted a statistically significant difference between median serum levels of UA when administered alone vs administered in the combination (2.7 ng/mL vs 43.8 ng/mL, p = 0.03). Individuals receiving the combination also had a favorable impact on gut microbiome status and a reduction in "microbiome score" predictive of prostate cancer risk.

3 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
FCFeroza Kaneez Choudhury
Feroza Kaneez Choudhury
G. Lavender HackmanG. Lavender Hackman
G. Lavender Hackman
ALAlessia Lodi
Alessia Lodi
STStefano Tiziani
Stefano Tiziani
A major hallmark of cancer is the metabolic reprogramming of cancer cells to fuel tumor growth and proliferation. Various plant-derived bioactive compounds efficiently target the metabolic vulnerabilities of cancer cells and exhibit potential as emerging therapeutic agents. Due to their safety and common use as dietary components, they are also ideal for cancer prevention. However, to render their use as efficient as possible, the mechanism of action of these phytochemicals needs to be well characterized. Stable isotope tracing is an essential technology to study the molecular mechanisms by which nutraceuticals modulate and target cancer metabolism. The use of positionally labeled tracers as exogenous nutrients and the monitoring of their downstream metabolites labeling patterns enable the analysis of the specific metabolic pathway activity, via the relative production and consumption of the labeled metabolites. Although stable isotope tracing metabolomics is a powerful tool to investigate the molecular activity of bioactive compounds as well as to design synergistic nutraceutical combinations, this methodology is still underutilized. This review aims to investigate the research efforts and potentials surrounding the use of stable isotope tracing metabolomics to examine the metabolic alterations mediated by bioactive compounds in cancer.

2 February 2024 in Science Advances
Verified
Journal Article
Open access
SSStephanie M. Stanford
Stephanie M. Stanford
TNTiffany P. Nguyen
Tiffany P. Nguyen
JCJoseph Chang
Joseph Chang
ZZZixuan Zhao
Zixuan Zhao
G. Lavender HackmanG. Lavender Hackman
G. Lavender Hackman
NBNunzio Bottini
Nunzio Bottini
Protein tyrosine phosphatases (PTPs) play major roles in cancer and are emerging as therapeutic targets. Recent reports suggest low–molecular weight PTP (LMPTP)—encoded by the ACP1 gene—is overexpressed in prostate tumors. We found ACP1 up-regulated in human prostate tumors and ACP1 expression inversely correlated with overall survival. Using CRISPR-Cas9–generated LMPTP knockout C4-2B and MyC-CaP cells, we identified LMPTP as a critical promoter of prostate cancer (PCa) growth and bone metastasis. Through metabolomics, we found that LMPTP promotes PCa cell glutathione synthesis by dephosphorylating glutathione synthetase on inhibitory Tyr 270 . PCa cells lacking LMPTP showed reduced glutathione, enhanced activation of eukaryotic initiation factor 2–mediated stress response, and enhanced reactive oxygen species after exposure to taxane drugs. LMPTP inhibition slowed primary and bone metastatic prostate tumor growth in mice. These findings reveal a role for LMPTP as a critical promoter of PCa growth and metastasis and validate LMPTP inhibition as a therapeutic strategy for treating PCa through sensitization to oxidative stress.